A Study to Find the Highest Dose of Biological Study Drug (EMD 273066) That Can Be Given Safely to Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given a Low Dose of Cyclophosphamide

Trial Profile

A Study to Find the Highest Dose of Biological Study Drug (EMD 273066) That Can Be Given Safely to Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given a Low Dose of Cyclophosphamide

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2013

At a glance

  • Drugs Tucotuzumab celmoleukin (Primary) ; Cyclophosphamide
  • Indications Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 05 Nov 2010 Actual initiation date (May 2005) added as reported by ClinicalTrials.gov.
    • 05 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Nov 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top